Sustained diurnal blood pressure reduction in SHR with ramipril assessed by telemetric monitoring

Clinical and Experimental Hypertension

Volumn 19, Issue 8, 1997, Pages 1233-1246

  Becker, R H A ^a   Baldes, L ^a   Furst U ^a   Schulze, K J ^a  

^a SANOFI   (France)

Author keywords

Cardiac reflex; Circadian; Converting enzyme inhibition; Ramipril; SHR; Telemetry

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART RATE; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TELEMETRY;

EID: 0030780256     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969709083215     Document Type: Article

References (36)

1. Pharmacological interference with the cardiac renin-angiotensin system. Becker-RH; Linz-W; Scholkens-BA. J-Cardiovasc-Pharmacol. 1989; 14 Suppl 4: S10-5.
2. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Frampton-JE; Peters-DH. Drugs. 1995; 49(3): 440-66.
3. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Lievre-M; Gueret-P; Gayet-C; Roudaut-R; Haugh-MC; Delair-S; Boissel-JP. Hypertension. 1995; 25(1): 92-7.
4. The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats. Nakamura-F; Nagano-M; Higaki-J; Higashimori-K; Morishita-R; Mikami-H; Ogihara-T. Clin-Exp-Pharmacol-Physiol. 1993; 20(3): 135-40.
5. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Baker-KM; Chernin-MI; Wixson-SK; Aceto-JF. Am-J-Physiol. 1990; 259(2 Pt 2): H324-32.
6. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Kromer-EP; Riegger-GA. Am-J-Cardiol. 1988 1; 62(1): 161-3.
7. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Linz-W; Scholkens-BA; Ganten-D. Clin-Exp-Hypertens-A. 1989; 11(7): 1325-50.
8. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Linz-W; Schaper-J; Wiemer-G; Albus-U; Scholkens-BA. Br-J-Pharmacol. 1992; 107(4): 970-5.
9. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors. Martorana-PA; Scholkens-BA. Agents-Actions-Suppl. 1992; 38 (Pt 3): 98-102.
10. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. Hartman-JC; Wall-TM; Hullinger-TG; Shebuski-R. J-Cardiovasc-Pharmacol. 1993; 21(6): 996-1003.
11. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Linz-W; Wiemer-G; Gohlke-P; Unger-T; Scholkens-BA. Pharmacol-Rev. 1995; 47(1): 25-49.
12. Long term fall in blood pressure. Plasma and tissue converting enzyme inhibition. Two rat studies with Ramipril. Becker RHA, Baldes L, Treudler M, Metzger G and Maier R. Eur J Pharmacol 183: 1309 (1990).
13. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3. 3.0]octane-3-carboxylic acid (Hoe 498). Scholkens-BA; Becker-RH; Kaiser-J. Arzneimittelforschung. 1984; 34(10B): 1417-25.
14. A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radio-telemetry. Brockway-BP; Mills-PA; Azar-SH. Clin-Exp-Hypertens-A. 1991; 13(5): 885-95.
15. A radiotelemetry system for chronic measurement of blood pressure and heart rate in the unrestrained rat validation of the method. Guiol-C; Ledoussal-C; Surge-JM. J-Pharmacol-Toxicol-Methods. 1992; 28(2): 99-105.
16. Circadian rhythms of blood pressure, heart rate, and locomotor activity in spontaneously hypertensive rats as measured with radio-telemetry. Van-den-Buuse-M. Physiol-Behav. 1994; 55(4): 783-7.
17. Salt appetite, body sodium, handling of a NaCI load, renin, and aldosterone in genetically and spontaneously hypertensive rats. Ledingham-JM; Simpson-FO; Hamada-M. J-Cardiovasc-Pharmacol. 1990; 16 Suppl 7: S6-8.
18. Effects of amlodipine on circadian rhythms in blood pressure, heart rate, and motility: a telemetric study in rats. Mattes-A; Lemmer-B. Chronobiol-Int. 1991; 8(6): 526-38.
19. Food and Drug Administration: Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Rockville, Maryland: Division of Cardio-Renal Drug Products, US Department of Helth and Human Services; 1988.
20. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. Unger-T; Ganten-D; Lang-RE; Scholkens-BA. J-Cardiovasc-Pharmacol. 1985; 7(1): 36-41.
21. Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril. Sugimoto-K; Kumagai-Y; Tateishi-T; Seguchi-H; Ebihara-A. J-Cardiovasc-Pharmacol. 1989; 13 Suppl 3: S40-4.
22. Autonomic and baroreflex function after captopril in hypertension. Warren-SE; O'Connor-DT; Cohen-IM. Am-Heart-J. 1983; 105(6): 1002-8.
23. Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside. Becker-RH; Struthers-AD; Brown-MJ. Br-J-Clin-Pharmacol. 1986; 22(4): 409-13.
24. Effects of enalaprilat on circadian profiles in blood pressure and heart rate of spontaneously and transgenic hypertensive rats. Lemmer-B; Witte-K; Makabe-T; Ganten-D; Mattes-A. J-Cardiovasc-Pharmacol. 1994; 23(2): 311-4.
25. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of Ramipril The Ramipril Trial Study Group. Sigurdsson-A; Amtorp-O; Gundersen-T; Nilsson-B; Remes-J; Swedberg-K. Br-Heart-J. 1994; 72(5): 422-7.
26. The effect of captopril on the reflex control heart rate: possible mechanisms. Ajayi-AA; Campbell-BC; Meredith-PA; Kelman-AW; Reid-JL. Br-J-Clin-Pharmacol. 1985 ; 20(1): 17-25.
27. ACE inhibitors and vagal activity: the effect of captopril and lisinopril on cardiovascular reflexes. Quadri-R; Papotti-GM; La-Grotta-A; Maule-S; Zanone-M; Valentini-M; Fonzo-D; Chiandussi-L. Ann-Ital-Med-Int. 1992; 7(3): 148-52.
28. The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects. Hasselgren-B; Edgar-B; Johnsson-G; Ronn-O. Eur-J-Clin-Pharmacol. 1993; 45(4): 327-32.
29. A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects. Bainbridge-AD; MacFadyen-RJ; Lees-KR; Reid-JL. Br-J-Clin-Pharmacol. 1991; 31(2): 148-53.
30. Antihypertensive synergism of ramipril and felodipine. A telemetric study in SHR. Becker RHA; Baldes L; Fürst U and Schulze K-J. Eur J Clin Invest 1996; 26 (Suppl 1): 131.
31. Role of endogenius bradykinin in human coronary vasomotor control. Groves-P, Kurz-S, Just-HJ, Drexler-H. Circulation. 1995; 92 (12) 3424-30.
32. Time profile of converting enzyme activity in target organs after low dose oral ramipril in normotensive rats. Becker RHA; Metzger G; Maier R; Speth O; Treudler M and Schölkens BA. Naunyn-Schmiedeberg's Arch Pharmacol 340(suppl); R 56 (1989).
33. Effects of the angiotensin II receptor antagonist Iosartan on 24-hour blood pressure profile of primary and secondary hypertensive rats. Schnecko-A; Witte-K; Lemmer-B. J-Cardiovasc-Pharmacol. 1995; 26(2): 214-21.
34. The effect of ramipril on ambulatory blood pressure: a multicenter trial. Burris-JF. J-Cardiovasc-Pharmacol. 1991; 18 Suppl 2: S131-3.
35. 24-Hour blood pressure control with ramipril: Comparison of once daily morning and evening administration. Myburgh-DP; Verho-M; Botes-JH; Erasmus TP; Luus HG. Curr-Ther-Res. 1995; 56(12) : 1298-1306.
36. Effect of acute and Ion-term administration of ramipril on circadian rhythm of blood pressure in essential hypertension. Cavazzini-D; Amadei-G; Manferdini-R; Musacci-G; Mele-D; Longhini-C. Advances in Therapy. 1995; 12(1): 11-21.